Tanshinone IIA regulates the TGF‑β1/Smad signaling pathway to ameliorate non‑alcoholic steatohepatitis‑related fibrosis

Xu,Lianjie; Zhang,Yurong; Ji,Nengbo; Du,Yan; Jia,Tao; Wei,Shanshan; Wang,Wei; Zhang,Shan; Chen,Wenhui

doi:10.3892/etm.2022.11413

Tanshinone IIA regulates the TGF‑β1/Smad signaling pathway to ameliorate non‑alcoholic steatohepatitis‑related fibrosis

Authors:
- Lianjie Xu
- Yurong Zhang
- Nengbo Ji
- Yan Du
- Tao Jia
- Shanshan Wei
- Wei Wang
- Shan Zhang
- Wenhui Chen
View Affiliations

Affiliations: Faculty of Basic Medicine, Yunnan University of Traditional Chinese Medicine, Kunming, Yunnan 650500, P.R. China, Department of Orthopedics, First Clinical Medical College of Yunnan University of Traditional Chinese Medicine, Kunming, Yunnan 650021, P.R. China
Published online on: June 1, 2022 https://doi.org/10.3892/etm.2022.11413
Article Number: 486
Copyright: © Xu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tanshinone IIA (TIIA) is a major component extracted from the traditional herbal medicine Salvia miltiorrhiza and has been indicated to play a role in the treatment of organ fibrosis. However, the evidence supporting its antifibrotic effect is insufficient and the underlying mechanism is unclear. To investigate the therapeutic effect of TIIA on non‑alcoholic steatohepatitis‑related fibrosis (NASH‑F), the present study used a methionine choline deficiency diet to induce NASH‑F in rats, and explored the effect of TIIA on the transforming growth factor‑β1 (TGF‑β1)/Smad signaling pathway. Wistar rats were randomly divided into control, NASH‑F and TIIA groups. After 8 weeks of treatment, the levels of serum markers associated with liver function and fibrosis were measured, liver fat vacuoles and inflammation were assessed by haematoxylin and eosin staining, and liver fibrosis was assessed by Masson's trichrome staining. TGF‑β1, Smad2, Smad3, Smad7 and α‑smooth muscle actin (α‑SMA) mRNA expression, and TGF‑β1, Smad2/3, phosphorylated (p)‑Smad2/3, Smad7 and α‑SMA protein levels were determined. The results revealed that TIIA could remarkably ameliorate liver fat vacuoles and inflammation in NASH‑F rats, and could decrease the levels of serum aspartate aminotransferase, alanine aminotransferase, total bilirubin, total bile acid, hyaluronic acid, type Ⅳ collagen, laminin and type III collagen, while increasing the levels of total cholesterol and triglycerides; however, this was not statistically significance. TIIA markedly suppressed the increased TGF‑β1, Smad2, Smad3 and α‑SMA mRNA expression levels observed in the liver of NASH‑F rats, while it increased the mRNA expression level of Smad7. Similarly, TIIA suppressed the increased TGF‑β1, p‑Smad2/3 and α‑SMA protein levels observed in the liver of NASH‑F rats, while it increased the protein expression level of Smad7 in vitro and in vivo. TIIA had no significant cytotoxic effect at 10, 20, 40 and 80 µmol/l on human LX‑2 cell. In conclusion, the findings of the present study indicated that TIIA alleviated NASH‑F by regulating the TGF‑β1/Smad signaling pathway. TIIA may be a useful tool in the prevention and treatment of NASH‑F.

View Figures

View References

1	Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, Zelber-Sagi S, Wai-Sun Wong V, Dufour JF, Schattenberg JM, et al: A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 73:202–209. 2020.PubMed/NCBI View Article : Google Scholar
2	Arab JP, Arrese M and Trauner M: Recent insights into the pathogenesis of nonalcoholic fatty liver disease. Annu Rev Pathol. 13:321–350. 2018.PubMed/NCBI View Article : Google Scholar
3	Powell EE, Wong VW and Rinella M: Non-alcoholic fatty liver disease. Lancet. 397:2212–2224. 2021.PubMed/NCBI View Article : Google Scholar
4	Thibaut R, Gage MC, Pineda-Torra I, Chabrier G, Venteclef N and Alzaid F: Liver macrophages and inflammation in physiology and physiopathology of non-alcoholic fatty liver disease. FEBS J: Apr 15, 2021 (Epub ahead of print).
5	Zhang CY, Yuan WG, He P, Lei JH and Wang CX: Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets. World J Gastroenterol. 22:10512–10522. 2016.PubMed/NCBI View Article : Google Scholar
6	Zhang Y, Miao H, Yan H, Sheng Y and Ji L: Hepatoprotective effect of forsythiae fructus water extract against carbon tetrachloride-induced liver fibrosis in mice. J Ethnopharmacol. 218:27–34. 2018.PubMed/NCBI View Article : Google Scholar
7	Liu J, Kong D, Qiu J, Xie Y, Lu Z, Zhou C, Liu X, Zhang R and Wang Y: Praziquantel ameliorates CCl₄-induced liver fibrosis in mice by inhibiting TGF-β/Smad signalling via up-regulating Smad7 in hepatic stellate cells. Br J Pharmacol. 176:4666–4680. 2019.PubMed/NCBI View Article : Google Scholar
8	Walton KL, Johnson KE and Harrison CA: Targeting TGF-β mediated SMAD signaling for the prevention of fibrosis. Front Pharmacol. 8(461)2017.PubMed/NCBI View Article : Google Scholar
9	Karin D, Koyama Y, Brenner D and Kisseleva T: The characteristics of activated portal fibroblasts/myofibroblasts in liver fibrosis. Differentiation. 92:84–92. 2016.PubMed/NCBI View Article : Google Scholar
10	Massagué J: TGF-β signalling in context. Nat Rev Mol Cell Biol. 13:616–130. 2012.PubMed/NCBI View Article : Google Scholar
11	Fabregat I, Moreno-Càceres J, Sánchez A, Dooley S, Dewidar B, Giannelli G and Ten Dijke P: IT-LIVER Consortium. TGF-β signalling and liver disease. FEBS J. 283:2219–2232. 2016.PubMed/NCBI View Article : Google Scholar
12	Giannelli G, Mikulits W, Dooley S, Fabregat I, Moustakas A, Ten Dijke P, Portincasa P, Winter P, Janssen R, Leporatti S, et al: The rationale for targeting TGF-β in chronic liver diseases. Eur J Clin Invest. 46:349–361. 2016.PubMed/NCBI View Article : Google Scholar
13	Yan C, Wang L, Li B, Zhang BB, Zhang B, Wang YH, Li XY, Chen JX, Tang RX and Zheng KY: The expression dynamics of transforming growth factor-β/Smad signaling in the liver fibrosis experimentally caused by clonorchis sinensis. Parasit Vectors. 8(70)2015.PubMed/NCBI View Article : Google Scholar
14	Li B, Yan C, Wu J, Stephane K, Dong X, Zhang YZ, Zhang Y, Yu Q and Zheng KY: Clonorchis sinensis ESPs enhance the activation of hepatic stellate cells by a cross-talk of TLR4 and TGF-β/Smads signaling pathway. Acta Trop. 205(105307)2020.PubMed/NCBI View Article : Google Scholar
15	El Nashar EM, Alghamdi MA, Alasmari WA, Hussein MMA, Hamza E, Taha RI, Ahmed MM, Al-Khater KM and Abdelfattah-Hassan A: Autophagy promotes the survival of adipose mesenchymal stem/stromal cells and enhances their therapeutic effects in cisplatin-induced liver injury via modulating TGF-β1/Smad and PI3K/AKT signaling pathways. Cells. 10(2475)2021.PubMed/NCBI View Article : Google Scholar
16	Dooley S, Hamzavi J, Breitkopf K, Wiercinska E, Said H, Lorenzen J, Ten Dijke P and Gressner AM: Smad7 prevents activation of hepatic stellate cells and liver fibrosis in rats. Gastroenterology. 125:178–191. 2003.PubMed/NCBI View Article : Google Scholar
17	Choi JH, Jin SW, Choi CY, Kim HG, Lee GH, Kim YA, Chung YC and Jeong HG: Capsaicin inhibits dimethylnitrosamine-induced hepatic fibrosis by inhibiting the TGF-β1/Smad pathway via peroxisome proliferator-activated receptor gamma activation. J Agric Food Chem. 65:317–326. 2017.PubMed/NCBI View Article : Google Scholar
18	Bai G, Yan G, Wang G, Wan P and Zhang R: Anti-hepatic fibrosis effects of a novel turtle shell decoction by inhibiting hepatic stellate cell proliferation and blocking TGF-β1/Smad signaling pathway in rats. Oncol Rep. 36:2902–2910. 2016.PubMed/NCBI View Article : Google Scholar
19	Peng Y, Yang T, Huang K, Shen L, Tao Y and Liu C: Salvia miltiorrhiza ameliorates liver fibrosis by activating hepatic natural killer cells in vivo and in vitro. Front Pharmaco. 9(762)2018.PubMed/NCBI View Article : Google Scholar
20	Yan Q, Mao Z, Hong J, Gao K, Niimi M, Mitsui T and Yao J: Tanshinone IIA stimulates cystathionine γ-lyase expression and protects endothelial cells from oxidative injury. Antioxidants (Basel). 10(1007)2021.PubMed/NCBI View Article : Google Scholar
21	Chen Z, Gao X, Jiao Y, Qiu Y, Wang A, Yu M, Che F, Li S, Liu J, Li J, et al: Tanshinone IIA exerts anti-inflammatory and immune-regulating effects on vulnerable atherosclerotic plaque partially via the TLR4/MyD88/NF-κB signal pathway. Front Pharmacol. 10(850)2019.PubMed/NCBI View Article : Google Scholar
22	Subedi L and Gaire BP: Tanshinone IIA: A phytochemical as a promising drug candidate for neurodegenerative diseases. Pharmacol Res. 169(105661)2021.PubMed/NCBI View Article : Google Scholar
23	Bi Z, Wang Y and Zhang W: A comprehensive review of tanshinone IIA and its derivatives in fibrosis treatment. Biomed Pharmacother. 137(111404)2021.PubMed/NCBI View Article : Google Scholar
24	Shi MJ, Yan XL, Dong BS, Yang WN, Su SB and Zhang H: A network pharmacology approach to investigating the mechanism of Tanshinone IIA for the treatment of liver fibrosis. J Ethnopharmacol. 253(112689)2020.PubMed/NCBI View Article : Google Scholar
25	Sun X, Tan Y, Lyu J, Liu HL, Zhao ZM and Liu CH: Active components formulation developed from fuzheng huayu recipe for anti-liver fibrosis. Chin J Integr Med: Sep 28, 2021 (Epub ahead of print).
26	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
27	Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM and Sanyal AJ: The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American association for the study of liver diseases. Hepatology. 67:328–357. 2018.PubMed/NCBI View Article : Google Scholar
28	Wong VW, Wong GL, Choi PC, Chan AW, Li MK, Chan HY, Chim AM, Yu J, Sung JJ and Chan HL: Disease progression of non-alcoholic fatty liver disease: A prospective study with paired liver biopsies at 3 years. Gut. 59:969–974. 2010.PubMed/NCBI View Article : Google Scholar
29	Taylor RS, Taylor RJ, Bayliss S, Hagström H, Nasr P, Schattenberg JM, Ishigami M, Toyoda H, Wai-Sun Wong V, Peleg N, et al: Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis. Gastroenterology. 158:1611–1625.e12. 2020.PubMed/NCBI View Article : Google Scholar
30	Li R, Li J, Huang Y, Li J, Yan S, Lin J, Chen Y, Wu L, Liu B, Wang G and Lan T: Polydatin attenuates diet-induced nonalcoholic steatohepatitis and fibrosis in mice. Int J Biol Sci. 14:1411–1425. 2018.PubMed/NCBI View Article : Google Scholar
31	Li X, Wang TX, Huang X, Li Y, Sun T, Zang S, Guan KL, Xiong Y, Liu J and Yuan HX: Targeting ferroptosis alleviates methionine-choline deficient (MCD)-diet induced NASH by suppressing liver lipotoxicity. Liver Int. 40:1378–1394. 2020.PubMed/NCBI View Article : Google Scholar
32	Zisser A, Ipsen DH and Tveden-Nyborg P: Hepatic stellate cell activation and inactivation in NASH-fibrosis-roles as putative treatment targets? Biomedicines. 9(365)2021.PubMed/NCBI View Article : Google Scholar
33	Czaja AJ: Hepatic inflammation and progressive liver fibrosis in chronic liver disease. World J Gastroenterol. 20:2515–2532. 2014.PubMed/NCBI View Article : Google Scholar
34	Eom YW, Shim K and Baik SK: Mesenchymal stem cell therapy for liver fibrosis. Korean J Intern Med. 30:580–589. 2015.PubMed/NCBI View Article : Google Scholar
35	Seki E and Brenner DA: Recent advancement of molecular mechanisms of liver fibrosis. J Hepatobiliary Pancreat Sci. 22:512–518. 2015.PubMed/NCBI View Article : Google Scholar
36	Xu S, Mao Y, Wu J, Feng J, Li J, Wu L, Yu Q, Zhou Y, Zhang J and Chen J: TGF-β/Smad and JAK/STAT pathways are involved in the anti-fibrotic effects of propylene glycol alginate sodium sulphate on hepatic fibrosis. J Cell Mol Med. 24:5224–5237. 2020.PubMed/NCBI View Article : Google Scholar
37	Friedman SL: Hepatic stellate cells: Protean, multifunctional, and enigmatic cells of the liver. Physiol Rev. 88:125–172. 2008.PubMed/NCBI View Article : Google Scholar
38	Li Z, Wang Z, Dong F, Shi W, Dai W, Zhao J, Li Q, Fang ZE, Ren L, Liu T, et al: Germacrone attenuates hepatic stellate cells activation and liver fibrosis via regulating multiple signaling pathways. Front Pharmacol. 12(745561)2021.PubMed/NCBI View Article : Google Scholar
39	Yu K, Li Q, Shi G and Li N: Involvement of epithelial-mesenchymal transition in liver fibrosis. Saudi J Gastroenterol. 24:5–11. 2018.PubMed/NCBI View Article : Google Scholar
40	Zhou QY, Yang HM, Liu JX, Xu N, Li J, Shen LP, Zhang YZ, Koda S, Zhang BB, Yu Q, et al: MicroRNA-497 induced by clonorchis sinensis enhances the TGF-β/Smad signaling pathway to promote hepatic fibrosis by targeting Smad7. Parasit Vectors. 14(472)2021.PubMed/NCBI View Article : Google Scholar